Working capital per share of Pennant Group Inc – FWB:1ZU
This article provides working capital per share data for Pennant Group Inc (FWB:1ZU) listed on the Frankfurt Stock Exchange. It includes financial information and links to various features and services offered by TradingView, such as charting tools, market data, and community resources.
JPMorgan Chase & Co. Has $3.30 Million Stock Holdings in The Pennant Group, Inc. $PNTG
JPMorgan Chase & Co. increased its stake in The Pennant Group, Inc. (NASDAQ:PNTG) by 288.4% in the third quarter, bringing its total holdings to 130,721 shares valued at approximately $3.30 million. The Pennant Group reported strong quarterly earnings, beating analyst estimates with an EPS of $0.34 and revenue of $289.3 million, and provided optimistic FY2026 EPS guidance. Analyst sentiment for PNTG is largely bullish, with a consensus "Moderate Buy" rating and a target price of $36.60.
The Pennant Group, Inc. (PNTG) stock price, news, quote and history
The Pennant Group, Inc. (PNTG) provides healthcare services, operating in Home Health and Hospice Services, and Senior Living Services segments across multiple US states. The stock closed at $29.66, down 2.27%, with an overnight price of $28.67. Analysts have an average target price of $37.83, with RBC Capital maintaining an "Outperform" rating and raising its price target to $41.
The Pennant Group (PNTG) Research Report
The Pennant Group (PNTG) reported strong Q4 CY2025 results, exceeding revenue and EPS estimates, though its full-year EBITDA guidance for 2026 was below analyst expectations. Despite impressive revenue growth and improving cash profitability, StockStory maintains an "Underperform" rating due to the company's subscale operations, high valuation, and an overleveraged balance sheet with a 6x net-debt-to-EBITDA ratio. The report advises investors to wait for improved cash flow generation or debt reduction before considering investment.
Pennant Group acquires Mesa senior living facility for $undisclosed By Investing.com
The Pennant Group, Inc. (NASDAQ:PNTG) announced the acquisition of Arbor Rose Senior Living in Mesa, Arizona, renaming it Lavender Lane Senior Living. This acquisition expands Pennant's presence in Arizona's East Valley market and includes 74 licensed beds and 25 independent living units. The financial terms were not disclosed, but the company emphasized its commitment to disciplined growth and the long-term fundamentals of the Arizona senior housing market, following a strong Q4 2025 financial performance.
Pennant Group acquires Mesa senior living facility for $undisclosed By Investing.com
The Pennant Group, Inc. (NASDAQ:PNTG) has acquired Arbor Rose Senior Living in Mesa, Arizona, renaming it Lavender Lane Senior Living. This acquisition expands Pennant's presence in Arizona's East Valley market, adding 74 licensed beds and 25 independent living units. The company continues its growth trajectory, with InvestingPro analysis suggesting PNTG is slightly undervalued.
Executive pay, board elections headline The Pennant Group (PNTG) 2026 proxy
The Pennant Group (PNTG) has released its 2026 proxy statement, detailing proposals for its annual meeting on May 14, 2026. Stockholders will vote on the election of three Class I directors, the ratification of Deloitte & Touche LLP as the independent auditor, and an advisory vote on executive compensation. The company emphasizes its performance-based executive pay structure and significant stockholder engagement.
Price-Driven Insight from (PNTG) for Rule-Based Strategy
This article provides a price-driven insight for The Pennant Group Inc. (NASDAQ: PNTG) using AI models, highlighting weak near and mid-term sentiment but a strong long-term outlook. It outlines three distinct institutional trading strategies—Position Trading, Momentum Breakout, and Risk Hedging—with specific entry, target, and stop-loss levels. The analysis emphasizes an exceptional risk-reward setup with a potential 12.1% gain against a 0.3% risk.
The Pennant Group (NASDAQ:PNTG) Lowered to Hold Rating by Wall Street Zen
Wall Street Zen downgraded The Pennant Group (NASDAQ:PNTG) from "buy" to "hold," although the consensus among seven analysts remains a "Moderate Buy" with an average price target of $36.60. The company reported strong Q4 2025 earnings, beating estimates with $0.34 EPS and $289.32 million in revenue, and provided FY2026 guidance of $1.26 to $1.36 EPS. Despite the downgrade from Wall Street Zen and Zacks, other firms like Truist, Wells Fargo, RBC, and Weiss Ratings have recently raised targets or upgraded the stock, reflecting varied analyst sentiments.
Vanguard disaggregates holdings; reports 0 shares of Pennant Group (PNTG) after realignment
The Vanguard Group has filed an amended Schedule 13G for Pennant Group Inc. (PNTG), reporting zero beneficial ownership of shares due to an internal realignment effective January 12, 2026. This realignment means certain subsidiaries and business divisions will now report their holdings separately, in accordance with SEC Release No. 34-39538. The filing clarifies a change in reporting structure rather than a sale of shares, and was signed by Ashley Grim on March 27, 2026.
Riverbridge Partners LLC Has $19.83 Million Position in The Pennant Group, Inc. $PNTG
Riverbridge Partners LLC reduced its stake in The Pennant Group, Inc. (NASDAQ:PNTG) by 5.1%, now holding 704,535 shares valued at $19.83 million, representing 2.04% ownership. Despite this, institutional investors collectively own 85.88% of the stock. Analysts are largely bullish, with a "Moderate Buy" rating and an average price target of $36.60, following recent positive earnings results where the company beat expectations and provided strong FY2026 guidance.
Tudor Investment Corp ET AL Buys 157,574 Shares of The Pennant Group, Inc. $PNTG
Tudor Investment Corp ET AL significantly increased its stake in The Pennant Group, Inc. (NASDAQ:PNTG) by 317.4%, acquiring an additional 157,574 shares to bring its total holding to 207,220 shares valued at $5.23 million. Other institutional investors also raised their positions, leading to 85.88% institutional ownership. This comes after The Pennant Group surpassed its quarterly EPS and revenue estimates and provided positive FY2026 guidance.
Is the Pennant Group (PNTG) a solid growth stock? 3 reasons to think "yes"
The article from MSN discusses whether The Pennant Group (PNTG) is a solid growth stock, offering three reasons to support this positive outlook. It likely delves into aspects like financial performance, market position, or future prospects to justify its growth potential.
Is The Pennant Group (PNTG) a Solid Growth Stock? 3 Reasons to Think "Yes"
The Pennant Group, Inc. (PNTG) is identified as a strong growth stock based on its favorable Zacks Growth Style Score and top Zacks Rank. Key reasons include projected double-digit EPS growth outpacing industry averages, an impressive asset utilization ratio indicating efficient operations, and positive trends in earnings estimate revisions. These factors suggest PNTG is well-positioned for outperformance in the market.
The Pennant Group, Inc. (NASDAQ:PNTG) Receives Consensus Recommendation of "Moderate Buy" from Analysts
The Pennant Group, Inc. (NASDAQ:PNTG) has received a "Moderate Buy" consensus recommendation from analysts, with an average 12-month price target of $36.60. Recent financial results show the company beat Q4 expectations for both EPS and revenue, and it has issued optimistic FY2026 guidance. Several analysts have recently upgraded their ratings or increased price targets for PNTG.
William Blair initiates coverage of Pennant Group (PNTG) with outperform recommendation
William Blair has initiated coverage of The Pennant Group (PNTG) with an "Outperform" rating. This new coverage suggests a positive outlook from the investment firm regarding the company's future performance.
Pennant Group outlines 22% revenue growth target for 2026 while focusing on integration and operational excellence
The Pennant Group (PNTG) has set an ambitious goal of achieving 22% revenue growth by 2026, aiming for $900 million in acute care services. This target emphasizes integration and operational excellence across its diverse portfolio of home health, hospice, and senior living businesses. The company plans to leverage its existing infrastructure and strategic initiatives to drive this significant expansion.
Pennant Group outlines 22% revenue growth target for 2026 while focusing on integration and operational excellence
Pennant Group has set a revenue growth target of 22% for 2026, aiming to achieve this through strategic integration and operational excellence. The company's focus will be on streamlining processes and enhancing efficiency across its operations. This growth projection signals Pennant Group's commitment to expanding its market presence and improving its financial performance.
Provident Investment Management Inc. Buys Shares of 265,065 The Pennant Group, Inc. $PNTG
Provident Investment Management Inc. has initiated a new position in The Pennant Group, Inc. (NASDAQ:PNTG) by purchasing 265,065 shares valued at approximately $6.69 million. This investment now constitutes 0.6% of Provident's portfolio, with the firm owning 0.77% of Pennant at the quarter's end. The Pennant Group recently exceeded earnings expectations and provided optimistic FY 2026 guidance, leading to a largely positive analyst sentiment with a "Moderate Buy" consensus rating and a target price of $36.60.
Pennant CEO and CFO set for 2026 Oppenheimer healthcare chat
The Pennant Group (NASDAQ: PNTG) announced that CEO Brent Guerisoli and CFO Lynette Walbom will participate in the 2026 Oppenheimer Annual Healthcare MedTech & Services Conference on March 18, 2026. They will be featured in a fireside chat at 10:40 a.m. ET, with a live webcast available for investors. Despite positive fundamental updates in the past, Pennant's stock has often seen negative reactions, suggesting a pattern of selling into good news.
UPDATE - Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference
The Pennant Group, Inc. announced its participation in the 2026 Oppenheimer Co. Annual Healthcare MedTech & Services Conference. CEO Brent Guerisoli and CFO Lynette Walbom will hold a fireside chat on March 18, 2026, at 10:40 a.m. Eastern Time, with a live webcast available for interested parties. Pennant Group is a holding company of independent operating subsidiaries providing healthcare services across the United States.
Pennant Group to Participate in the 2026 Oppenheimer Annual Healthcare Conference
The Pennant Group, Inc. announced its participation in the 2026 Oppenheimer Co. Annual Healthcare MedTech & Services Conference. CEO Brent Guerisoli and CFO Lynette Walbom will hold a fireside chat on March 18, 2026, which will be accessible via live webcast. The company is a holding company of independent operating subsidiaries providing healthcare services across the U.S.
Algert Global LLC Buys 336,072 Shares of The Pennant Group, Inc. $PNTG
Algert Global LLC significantly increased its stake in The Pennant Group, Inc. (NASDAQ:PNTG) by 392.5%, acquiring an additional 336,072 shares. Other institutional investors also adjusted their holdings in PNTG, which has seen its stock price fluctuate and maintains a "Moderate Buy" analyst rating. The company recently reported better-than-expected quarterly earnings and provided FY 2026 guidance.
The Pennant Group Stock (ISIN: US70805F1066) Faces Headwinds in Home Health Sector Amid US Healthcare Shifts
The Pennant Group, a US-based provider of home health and hospice services, is experiencing significant challenges due to regulatory reimbursement cuts and rising operational costs. The article highlights the company's volatile stock performance and the necessity for European investors to closely monitor US Medicare policy changes. Despite steady revenue growth and strong hospice segment performance, the company faces pressures on EBITDA margins from wage inflation and therapy utilization constraints.
Pennant Group (PNTG) CEO granted 20,052 shares and 45,000 options
Pennant Group, Inc.'s CEO, Brent Guerisoli, recently received a grant of 20,052 shares of common stock that vested immediately and a stock option for 45,000 shares with an exercise price of $33.30. These equity awards are classified as compensation, not open-market trades, and significantly increased his direct common stock holdings to 102,030 shares. The stock options will vest in five equal annual installments starting March 5, 2027, and expire in 2036.
Pennant Group (PNTG) CFO granted 14,292 shares and 34,000 options
Pennant Group, Inc. (PNTG) CFO Lynette Walbom received 14,292 shares of common stock and 34,000 stock options. The shares, granted on March 3, 2026, vested immediately, bringing her direct holdings to 16,955 common shares. The stock options, granted on March 5, 2026, have an exercise price of $33.30 and will vest in five equal annual installments starting March 5, 2027.
Pennant Group (PNTG) EVP granted common shares and 30,000-share option
Pennant Group's EVP, General Counsel, and Corporate Secretary, Kirk Sterling Cheney, received equity compensation awards including 4,085 shares of common stock that vested immediately on March 3, 2026, increasing his direct holdings to 21,005 shares. Additionally, he was granted a stock option for 30,000 shares with an exercise price of $33.30, which will vest in five equal annual installments starting March 5, 2027, and expire on March 5, 2036. This announcement highlights significant insider equity grants for a key executive.
Pennant Group Stock Analysis: Strong Performance vs. Scale & Debt Risks - News and Statistics
The Pennant Group's stock has notably outperformed the S&P 500 recently, driven by strong quarterly results. Despite this performance, the company faces challenges due to its small size within the healthcare sector, which may hinder customer trust and economies of scale. Furthermore, concerns exist regarding its modest cash profitability compared to peers and a financial structure heavily reliant on debt, posing risks if market conditions deteriorate.
(PNTG) as a Liquidity Pulse for Institutional Tactics
This article provides an institutional analysis of The Pennant Group Inc. (NASDAQ: PNTG), identifying strong sentiment across all horizons supportive of an overweight bias. It outlines detailed trading strategies including position, momentum breakout, and risk hedging, along with multi-timeframe signal analysis for near, mid, and long-term periods. The analysis highlights an elevated downside risk despite strong sentiment.
The Pennant Group Soars 10.56% to Intraday High of $35.00
The Pennant Group, a small-cap company in the Pharmaceuticals & Biotechnology sector, saw its stock rise by 10.56% to an intraday high of $35.00, significantly outperforming the S&P 500. The company has demonstrated strong financial performance with positive quarterly results, high net sales, and robust operating cash flow. Its low debt-equity ratio and solid return on equity underscore its strong market position and consistent growth over the past three years.
Does Pennant’s 2026 Revenue Outlook After Strong 2025 Results Shift The Bull Case For PNTG?
Pennant Group (PNTG) reported strong 2025 financial results, but their 2026 revenue guidance of US$1.13 billion to US$1.17 billion, while reflecting growth from recent acquisitions, fell short of market expectations for adjusted EBITDA. This cautious outlook raises concerns about near-term profitability and its impact on the investment narrative, despite the company's long-term growth strategy centered on acquisitions and a decentralized model in home health and hospice. The article highlights the differing analyst opinions and the importance of analyzing various forecasts to form an individual investment decision.
Pennant Group Inc stock hits 52-week high at 32.29 USD
Pennant Group Inc. (PNTG) recently reached a 52-week high of $32.29, marking a significant performance over the past year with a 21.91% price return and a market capitalization of $1.1 billion. The healthcare services provider has demonstrated strong growth, supported by revenue growth of 29.89% and positive analyst ratings, including an "Outperform" from RBC Capital and an upgrade to "Overweight" from Wells Fargo, with an upcoming earnings report on March 4th.
The Pennant Group (NASDAQ:PNTG) Given New $41.00 Price Target at Royal Bank Of Canada
Royal Bank of Canada has increased its price target for The Pennant Group (NASDAQ:PNTG) to $41.00 from $39.00, maintaining an "outperform" rating. This adjustment follows the company's recent earnings beat, reporting $0.34 EPS against an expected $0.31, and raising its FY2026 guidance. Analyst consensus for PNTG is a "Moderate Buy" with an average price target of $36.60.
Pennant Group CEO: Don’t Overlook Our Senior Living Growth, Progress
Pennant Group CEO Brent Guerisoli highlights "substantial opportunity" for growth in the company's senior living sector, noting that demand consistently outpaces inventory growth. The company's strategy of clustering communities and empowering local leadership contributes to organic expansion. Pennant Group saw significant improvements in senior living metrics, including occupancy, revenue, and adjusted EBITDA, in Q4 2025.
Is Pennant Group (PNTG) Priced Attractive After Strong 1 Year Share Price Rally
Pennant Group (PNTG) has seen a 48% return over the last year, prompting an analysis of its valuation. A Discounted Cash Flow (DCF) model suggests the stock is significantly undervalued by 58.2%, with an estimated intrinsic value of $80.56 per share against a market price of $33.71. However, its Price/Earnings ratio of 39.51x is above the healthcare industry average and its proprietary "Fair Ratio" of 24.78x, indicating it might be overvalued by this metric.
The Pennant Group, Inc. Hits New 52-Week High at $33.30
The Pennant Group, Inc., a small-cap pharmaceuticals and biotechnology company, has reached a new 52-week high of $33.30, marking a 44.75% increase over the past year. The company's strong performance is supported by a market capitalization of $1,118 million, a P/E ratio of 26.00, a return on equity of 10.40%, and a low debt-to-equity ratio of 0.14. Despite not offering a dividend, its price-to-book ratio of 3.47 indicates growth potential.
Pennant Group (NASDAQ: PNTG) delivers 36% 2025 revenue growth and higher 2026 outlook
The Pennant Group (NASDAQ: PNTG) reported robust financial results for the full year 2025, with total revenue increasing 36.3% to $947.7 million and diluted EPS reaching $0.84, or $1.18 adjusted. The company also provided an optimistic outlook for 2026, projecting revenue between $1,133.6 million and $1,171.8 million and adjusted diluted EPS in the range of $1.26–$1.36, incorporating recent acquisitions. Growth was primarily driven by strong performances in its home health, hospice, and senior living segments, despite increased long-term debt due to acquisition-driven expansion.
The Pennant Group, Inc. (NASDAQ:PNTG) Q4 2025 Earnings Call Transcript
The Pennant Group, Inc. reported an exceptional Q4 and full year 2025, with adjusted EPS exceeding guidance and significant growth across both Home Health and Hospice and Senior Living segments due to strategic acquisitions and strong organic performance. The company provided optimistic 2026 guidance, projecting increased revenue and EBITDA, driven by ongoing integration of newly acquired operations and continued focus on operational excellence and leadership development. Pennant also emphasized its unique local operating model as a competitive advantage, particularly in light of industry consolidation by payers, and expressed confidence in future market share gains and strategic growth opportunities.
Pennant Group to focus on optimizing performance in 2026, but acquisitions aren’t off the table, CEO says
Pennant Group CEO Brent Guerisoli announced that the company will prioritize optimizing performance and operational excellence in its senior living portfolio in 2026, following a record-breaking 2025. While focusing on internal growth, the company remains open to selective acquisitions. The senior living segment showed significant growth in 2025, with revenue increasing 22.3% and occupancy rising to 80.6%.
The Pennant Group Q4 Earnings Beat Estimates, Shows Strong Growth - News and Statistics
The Pennant Group reported strong Q4 results, surpassing revenue and adjusted earnings per share estimates, and achieving record annual performance. The company's long-term growth trends demonstrate sustained customer appeal and accelerated revenue growth, partly due to pricing adjustments. While full-year revenue aligns with analyst projections, next year's EBITDA guidance is below current expectations.
Pennant Group Posts Record 2025 Results, Eyes 2026 Growth
Pennant Group (PNTG) reported record full-year 2025 results, with diluted EPS of $0.84 and adjusted EPS of $1.18, and total revenue rising 36.3% to $947.7 million. This growth was driven by strategic acquisitions and expansion in home health, hospice, and senior living sectors. The company expects continued revenue and adjusted EBITDA growth in 2026 as it integrates new operations and maintains performance.
Why The Pennant Group (PNTG) Shares Are Sliding Today
The Pennant Group (PNTG) shares fell sharply after the company reported strong fourth-quarter 2025 results that beat expectations but provided a weaker-than-anticipated financial outlook for 2026. While Q4 revenue grew significantly and adjusted EPS surpassed estimates, investors reacted negatively to the 2026 adjusted EBITDA guidance falling below analyst projections. This unexpected forecast overshadowed the positive quarterly performance, leading to a notable decline in the stock's value.
The Pennant Group, Inc. Announces Advance In Q4 Profit
The Pennant Group, Inc. (PNTG) reported a significant increase in its fourth-quarter profit, with earnings rising to $8.64 million from $5.76 million in the prior year. Adjusted earnings reached $12.16 million, or $0.34 per share, and revenue grew by 53.2% to $289.32 million.
The Pennant Group Inc. (PNTG) Stock Falls on Q4 2025 Earnings
The Pennant Group Inc. (PNTG) reported its Q4 2025 earnings, showing significant year-over-year revenue and operating profit growth, but a substantial decrease in net income attributable to common shareholders. While revenue beat analyst estimates, diluted EPS missed expectations, causing the stock to fall 1.8% after market close. Institutional investors showed mixed activity, with some significant reductions and additions to their holdings, and Wall Street analysts maintain primarily "Buy" or "Outperform" ratings with a median price target of $38.0.
Press Release: Pennant Reports Fourth Quarter and Fiscal Year 2025 Results
Pennant reported its fourth-quarter and fiscal year 2025 financial results. The company's fourth-quarter revenue increased 35% year-over-year to $609 million, exceeding analyst estimates. However, Pennant reported a quarterly loss of 66 cents per share.
Earnings Flash (PNTG) The Pennant Group, Inc. Posts Q4 Adjusted EPS $0.34 per Share, vs. FactSet Est of $0.32
The Pennant Group, Inc. (PNTG) announced its Q4 adjusted EPS of $0.34 per share, surpassing the FactSet estimate of $0.32. This financial news highlights the company's better-than-expected performance in the fourth quarter. The article also mentions the company's Q4 revenue of $289.3M, which also exceeded the FactSet estimate.
The Pennant Group's (NASDAQ:PNTG) Q4 CY2025 Sales Top Estimates
The Pennant Group (NASDAQ:PNTG) reported strong Q4 CY2025 results, with revenue of $289.3 million exceeding analyst estimates by 5.1% and representing a 53.3% year-on-year increase. The company's non-GAAP EPS of $0.34 also beat consensus estimates by 7.7%. While full-year revenue guidance is near analyst estimates, EBITDA guidance for 2026 is slightly below expectations, and shares traded down slightly after the report.
Pennant Group Inc stock hits 52-week high at 33.05 USD
Pennant Group Inc. (PNTG) stock reached a 52-week high of $33.05, driven by strong investor confidence and positive market sentiment. Trading at a P/E ratio of 43.79, the healthcare company has seen significant growth, with a 29.06% increase over the past year. RBC Capital reiterated an Outperform rating with a $39 price target, citing potential upside from recent acquisitions.
The Pennant Group Earnings: Q4 2025 Results & Analysis - News and Statistics
The Pennant Group is set to announce its Q4 2025 earnings, with market expectations predicting a 45.8% year-over-year revenue growth. The company has a history of surpassing analyst expectations and has seen its share price increase by 6.6% in the last month, in contrast to the broader healthcare segment's underperformance. The average analyst price target for The Pennant Group is $37.50, significantly higher than its current share price of $32.56.
The Pennant Group (PNTG) Q4 Earnings Report Preview: What To Look For
The Pennant Group (PNTG) is set to announce its Q4 earnings results, with analysts expecting a 45.8% year-on-year revenue growth. The company has a history of exceeding Wall Street's expectations and has outperformed its healthcare peers recently. Investors will be watching for insights into continued growth despite broader market uncertainties.
